drugset / Trial / NCT03921073

Study of T-VEC in Locally Advanced Cutaneous Angiosarcoma

NCT03921073

NaSingle-groupOpen-labelTreatment

Summary

This is a single-arm study evaluating the efficacy of injecting Talimogene Laherparepvec T-VEC into Cutaneous Angiosarcoma tumors.

Timeline

Start
2019-08-20
Primary completion
2021-09-28
Completion
2021-09-28

Drugs

EvaluationDrugModalityDoseRoute
Subject Talimogene Laherparepvec Other / unclassified 4 ml Other

Indications